Related Experiment Video
Updated: May 27, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
[What is the role of active surveillance for small renal masses?]
C Maurin1, F Vidal, E Lechevallier
1Service d'urologie professeur Coulange, centre hospitalo-universitaire de la Conception, Marseille cedex, France. Charlotte.MAURIN@ap-hm.fr
Abstract:
Incidence of small renal masses (SRM) T1a is increasing in every age group. In relation to their characteristics, treatments seem to become less invasive. This article summarizes data about Watchful Waiting. A literature review based on Pubmed and keywords "petites masses rénales", "small renal masses", "rein", "kidney", "tumeur", "tumor", "surveillance", "watchful waiting" was done. Fifty-eight english and french articles including cohort-following and meta-analysis were selected. Considering indolence and harmless of the SRM, watchful waiting is nowadays a valid therapeutic option: in most of the series is tumoral growing lower than 0.40cm per year, metastatic evolution approaches 1 to 2% (except in the Kouba et al. study with 5,7%) and disease-free survival is 100%. Nevertheless, this option seems to be appropriate after carefully selection of the patients (age, conciliance, comorbidities, imperative indications…) and the tumors (tumor size, localization, histology…). Watchful waiting is a promising alternative after selection of the SRM. Large-scale and long-term studies will precise the global cost and modalities of this therapeutic option.
Insights
Watchful waiting is a safe option for small renal masses (SRM), with slow growth and low metastatic risk. Careful patient and tumor selection are key for this less invasive approach.
Area of Science:
- Urology
- Oncology
Context:
- Increasing incidence of small renal masses (SRM) T1a across all age groups.
- Trend towards less invasive treatments for SRMs based on their characteristics.
Purpose:
- To summarize current data on the Watchful Waiting (WW) approach for SRMs.
- To evaluate the efficacy and safety of WW as a therapeutic option.
Summary:
- Literature review of 58 English and French articles (cohorts, meta-analyses) on WW for SRMs.
- SRMs exhibit indolent behavior: tumor growth <0.40cm/year, metastatic evolution ~1-2%, 100% disease-free survival.
- WW is a valid option but requires careful selection of patients (age, comorbidities) and tumors (size, histology).
Impact:
- Watchful waiting offers a promising, less invasive alternative for selected SRMs.
- Further large-scale, long-term studies are needed to refine cost and management protocols for WW.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Imaging Studies II: Ultrasonography
Urinary Tract Calculi VI: Surgical Management
Chronic Kidney Disease III: Interprofessional Care
Imaging Studies I: Kidney, Ureter, and Bladder Studies

